Edition:
India

Sino Biopharmaceutical Ltd (1177.HK)

1177.HK on Hong Kong Stock

8.87HKD
17 Jul 2019
Change (% chg)

HK$-0.06 (-0.67%)
Prev Close
HK$8.93
Open
HK$8.80
Day's High
HK$8.97
Day's Low
HK$8.76
Volume
23,227,039
Avg. Vol
53,273,428
52-wk High
HK$12.36
52-wk Low
HK$4.53

Latest Key Developments (Source: Significant Developments)

Sino Biopharmaceutical Announces Drug Registration Approval For Its Anti-Infective Drug
Tuesday, 16 Jul 2019 

July 16 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::"MOXIFLOXACIN HYDROCHLORIDE INJECTION" OBTAINS APPROVAL FOR DRUG REGISTRATION BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION.  Full Article

Sino Biopharmaceutical Says Anlotinib Hydrochloride Capsules Obtained Approval For New Indication
Friday, 5 Jul 2019 

July 5 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::ANLOTINIB HYDROCHLORIDE CAPSULES GOT APPROVAL FOR DRUG REGISTRATION FOR NEW INDICATION FOR TREATMENT OF "SOFT TISSUE SARCOMA".APPROVAL FOR DRUG REGISTRATION GRANTED BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PRC.  Full Article

Sino Biopharmaceutical Says Unit's Drug Approved For Drug Registration
Thursday, 4 Jul 2019 

July 4 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::UNIT'S ANTITHROMBOTIC DRUG "TICAGRELOR TABLET" APPROVED FOR DRUG REGISTRATION BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION.  Full Article

Sino Biopharmaceutical Says "Tadalafil Tablet" Obtains Approval For Drug Registration
Wednesday, 3 Jul 2019 

July 3 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::SINO BIOPHARMACEUTICAL LTD SAYS "TADALAFIL TABLET" OBTAINS APPROVAL FOR DRUG REGISTRATION.APPROVAL OBTAINED FROM NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PEOPLE'S REPUBLIC OF CHINA.  Full Article

Sino Biopharmaceutical Says Unit's Tenofovir Tablet Got EU Marketing Authorization
Thursday, 23 May 2019 

May 23 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::TENOFOVIR DISOPROXIL FUMARATE TABLET DEVELOPED BY UNIT HAS OBTAINED MARKETING AUTHORIZATION ISSUED BY EUROPEAN UNION.  Full Article

Sino Biopharmaceutical Posts Qtrly Underlying Profit Attributable RMB976.38 Mln
Tuesday, 21 May 2019 

May 21 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::QTRLY REVENUE RMB6,208.03 MILLION, AN INCREASE OF ABOUT 33.4%.QTRLY UNDERLYING PROFIT ATTRIBUTABLE RMB976.38 MILLION, UP 22.4%.BOARD HAS DECLARED PAYMENT OF A QUARTERLY DIVIDEND OF HK2 CENTS PER SHARE FOR THREE MONTHS ENDED 31 MARCH, 2019.  Full Article

Sino Biopharmaceutical Says Drug Developed By Unit Gets Approval For Drug Registration
Thursday, 9 May 2019 

May 9 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::'AMBRISENTAN TABLET' DEVELOPED BY UNIT GETS APPROVAL FOR DRUG REGISTRATION BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PRC.  Full Article

Sino Biopharmaceutical Says Drug Developed By Unit Received Approval For Registration
Wednesday, 9 Jan 2019 

Jan 9 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::LINEZOLID & GLUCOSE INJECTION OF UNIT RECEIVED APPROVAL FOR DRUG REGISTRATION BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION.  Full Article

Sino Biopharmaceutical Updates On Price And Volume Movements Of Shares Of Co
Thursday, 6 Dec 2018 

Dec 6 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::TWO PRODUCTS OF GROUP ARE SUCCESSFUL BIDDERS IN TENDER FOR CENTRALISED PROCUREMENT OF MEDICINES IN PILOT CITIES OF CHINA.SAVE AS DISCLOSED, NOT AWARE OF ANY REASONS FOR PRICE OR VOLUME MOVEMENTS OF SHARES OF CO.  Full Article

Sino Biopharmaceutical Says Iodixanol Injection Obtained Approval For Drug Registration
Tuesday, 3 Jul 2018 

July 3 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::IODIXANOL INJECTION OBTAINED APPROVAL FOR DRUG REGISTRATION BY NATIONAL DRUG ADMINISTRATION OF PRC.  Full Article

Hong Kong shares end lower as Huawei charges fan trade worries

* HSI financial sector sub-index is flat; property sector up 0.5 percent